# Fennec Pharmaceuticals Inc. (FENC) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $12.39, market value $434 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Fennec Pharmaceuticals Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 7.3×**. Each dollar of revenue is priced at 7.3×.
- **Price / book: 10.2×**. The shares trade at 10.2× book value; most of the value is in earnings power and intangibles rather than the balance sheet.

## Profitability
- **Operating margin: -1.9%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -21.8%**. The company reported a net loss over the last twelve months.
- **Return on equity: -27.5%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -4.9%**. Return on all capital, debt included, is -4.9%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -4.6%**. Each dollar of assets produces -4.6% of profit.

## Growth
- **Revenue growth (1 yr): -6.1%** (3-yr 207.5%/yr, 5-yr 204.7%/yr). Revenue fell 6.1% over the last year, against 204.7% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -1600.0%**. Earnings per share fell 1600.0%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.55**. Debt is 0.55 times equity, moderate leverage.
- **Current ratio: 6.37** (quick 6.37). Current assets cover the next year's liabilities 6.37 times.
- **Altman Z-score: 9.44**. A Z-score of 9.44 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Fennec Pharmaceuticals Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 35.0%** (YTD 60.9%, 3-mo 42.4%). The shares are up 35.0% over twelve months including dividends.
- **From 52-week high: -6.5%** (119.3% above the low). Trading 6% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 60**. An RSI of 60 is neutral.
- **Beta (1 yr): 1.47** (volatility 66%). Beta of 1.47 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=FENC · Page: https://foliofundamentals.com/stocks/fenc

Not investment advice.